Investment Analysis: Alivus Life Sciences (ALIVUS)

Analysis Date: August 07, 2026
Event Evaluated: Q1 FY27 Concall Update & ₹540 Cr Capex Announcement

1. Executive Summary & Verdict Rationale

Alivus Life Sciences (formerly Glenmark Life Sciences) has announced a ₹540 Cr capex plan for FY27 alongside stellar Q1 FY27 profitability margins (36.6% EBITDA margin). The strategic transition to non-Glenmark Pharma (non-GPL) business is progressing rapidly (+26.5% YoY), offsetting severe drag from GPL inventory rationalization (-52.6% YoY).

With a superior ROCE profile of 25.0%, minimal debt (D/E 0.02), high promoter ownership (74.9%), and high-margin CDMO/potent API mix, Alivus qualifies as a POSSIBLE multibagger compounder candidate.

2. Catalyst Math & Ramp-Aware Execution

• FY26 Baseline Revenue: ~₹2,552 Cr
• FY27 Management Guidance: 10%–12% Top-line growth (~₹2,820 Cr)
• Capex Size: ₹540 Cr (~21.1% of base revenue)
• Asset Turnover Potential: ~2.0x–2.4x historical asset turn
• Incremental Revenue Potential: ₹540 Cr × 2.0x = ₹1,080 Cr steady-state revenue addition over 2.5–3.0 years.
• Steady-State Revenue Level: ~₹3,500–3,600 Cr (+38% uplift over current TTM base).
• Margin Assumptions: Sustained EBITDA margin of 32–34% and net profit margin of 21–22%.
• Steady-State EPS Impact: ~42% expansion once Solapur and expanded facilities reach >70% utilization by FY28/29.

3. Minervini SEPA & Quality Gate Evaluation

• ROCE: 25.0% (Passed Quality Gate)
• Balance Sheet Health: D/E 0.02, Net Worth ₹3,333 Cr, pristine leverage metrics.
• Earnings Acceleration: Q1 FY27 PAT rose 31.8% YoY to ₹160.1 Cr despite top-line growing only 6.4%, driven by strong margin expansion.
• Fundamental Grade: A

4. Valuation Scenarios (18–36 Month Horizon)

• Base Case (+45% Upside): Solapur facility ramps up smoothly; non-GPL growth sustains >20%; GPL rationalization normalizes. Revenue reaches ₹3,500 Cr with 22% PAT margin.
• Bull Case (+85% Upside): CDMO revenue contribution exceeds 15% of total mix; high-potent API launches accelerate in Japan/US; EBITDA margins hold above 35%, leading to significant earnings re-rating.
• Bear Case (-15% Downside): Prolonged delay in Solapur commercial ramp-up combined with continued margin pressure on legacy APIs and further customer inventory cuts.

5. Final Assessment

Alivus presents a high-quality balance sheet expanding into high-margin CDMO/potent API categories. While short-term top-line growth is moderated by GPL inventory adjustments, the non-GPL engine is firing, and the ₹540 Cr capex provides clear multi-year growth visibility.

Alivus Life Sciences (ALIVUS) - Detailed Equity Research Report

Analysis Date: 2026-07-30 Current Price: ₹1,119.6 Promoter Holding: 74.87% ROCE: 25.0% | D/E: 0.02 | Cash Balance: ₹880.2 Cr

1. Ramp-Aware Impact Math & Catalyst Valuation

• Quarterly Performance (Q1 FY27):
• Net Profit surged 31.8% YoY to ₹160.1 Cr (PAT Margin: 25.0%).
• Revenue grew 6.4% YoY to ₹640.4 Cr.
• Record EBITDA Margin of 36.6% (vs guided range of 30-32%), driven by operating leverage and favorable product mix in the Non-GPL segment.

• Non-GPL segment surged 26.5% YoY, counterbalancing soft performance in the GPL segment.

• Capacity Expansion Impact (Solapur):

• Existing Installed Capacity: 1,424 KL.
• Solapur Expansion: Phase 1 (350 KL) + Phase 2 (115 KL) = 465 KL (+32.65% capacity increment).

• Target Completion: Q4 FY27.

• Revenue & EPS Ramp Model:

• Year 1 (FY27): Minimal direct contribution from Solapur due to Q4 completion. Management guides overall FY27 revenue growth at 10-12%. Year-1 incremental uplift from Solapur is estimated at ~3% (~₹75 Cr).
• Steady-State (FY28-FY29): At historical asset turnover of ~2.0x-2.4x, the additional 465 KL capacity can generate ₹500-600 Cr in steady-state annual revenue (~25% uplift over FY26 base of ₹2,552 Cr).
• PAT & EPS Uplift: Assuming normalized EBITDA margin of ~32% and PAT margin of ~21%, incremental steady-state PAT will be ~₹110-125 Cr, boosting baseline EPS by ~22-25%.

2. Industry Context & Moat Evaluation

• Industry Structure: Bulk Drugs & Active Pharmaceutical Ingredients (API) / CDMO.
• Capital Intensity: MEDIUM. Requires specialized manufacturing blocks, environmental clearances, and GMP validations.
• Execution Difficulty: MODERATE. Regulatory filings (DMFs/CEP) and audits by regulatory bodies (USFDA, Japan PMDA) impose validation timelines of 6-12 months per molecule before full commercial production.
• Structural Growth Rate: Indian API/CDMO industry expected CAGR is 8-10%, supported by China+1 supply chain diversification and rising CDMO outsourcing by global innovator pharma.

3. Fundamental Quality & Balance Sheet Assessment

• ROCE: 25.0%, meeting high quality standards.
• Balance Sheet Strength: Virtually net debt-free (Debt: ₹57 Cr vs Cash: ₹880.2 Cr; D/E: 0.02).
• Promoter Holding: High at 74.87%, indicating tight promoter alignment.
• Moat Sustainability: Strong regulatory footprint with USFDA-approved sites in Ankleshwar, Dahej, and Mohol; regulated markets contribute 81% of total revenue.
• Customer Risk: Dependency on former parent Glenmark Pharma (GPL) stands at 24.4%. High growth in Non-GPL (+26.5%) is successfully diluting this concentration.

4. Scenario Analysis & Price Targets

• Base Case (+35% Upside over 24 months):
• FY27 revenue grows 11% in line with guidance; Solapur Phase 1 & 2 operationalized on schedule in Q4 FY27.
• EBITDA margins normalize around 32-33%.

• Non-GPL CDMO growth remains steady at 15-18% CAGR.

• Bull Case (+65% Upside over 24-36 months):

• Accelerated client onboarding at Solapur and higher CDMO revenue contribution boost revenue CAGR to 16-18%.
• EBITDA margins sustain at elevated 34-36% levels due to high-margin chronic API mix.

• Potential multi-bagger engine activates as earnings re-rate alongside capacity deployment.

• Bear Case (-15% Downside):

• Prolonged customer destocking at GPL and pricing pressure on mature APIs reduce revenue growth to 4-5%.
• Delay in commercial validation at Solapur reduces asset turnover.

5. Final Verdict & Rationale

• தீர்ப்பு: POSSIBLE
• Multibagger Score: 68/100
• Rationale: Alivus Life Sciences is a structurally sound, highly profitable API/CDMO player with pristine return metrics (ROCE 25%) and robust cash reserves. While current growth guidance (10-12% top-line) is steady rather than hyper-growth, the +32.6% Solapur capacity expansion coming online in late FY27 offers medium-term growth acceleration. Continued non-GPL growth (+26.5%) and CDMO expansion provide a realistic path toward significant compounding, placing the stock firmly in the 'POSSIBLE' multibagger category.